Janus Henderson Group PLC Purchases 211,068 Shares of Abivax SA Sponsored ADR $ABVX

Janus Henderson Group PLC grew its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 31.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 878,829 shares of the company’s stock after purchasing an additional 211,068 shares during the quarter. Janus Henderson Group PLC’s holdings in Abivax were worth $98,007,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. UBS Group AG boosted its holdings in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after buying an additional 4,293,606 shares during the last quarter. Morgan Stanley increased its holdings in Abivax by 114.3% during the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after buying an additional 1,681,277 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new position in Abivax in the third quarter worth approximately $132,800,000. TCG Crossover Management LLC raised its position in Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after acquiring an additional 1,055,000 shares during the period. Finally, Westfield Capital Management Co. LP purchased a new position in shares of Abivax during the 4th quarter worth $136,199,000. Institutional investors own 47.91% of the company’s stock.

Abivax Stock Up 0.5%

NASDAQ ABVX opened at $124.92 on Friday. The firm has a market cap of $10.90 billion, a price-to-earnings ratio of -23.98 and a beta of 0.87. The business has a 50-day moving average price of $118.54 and a 200-day moving average price of $118.41. Abivax SA Sponsored ADR has a twelve month low of $67.09 and a twelve month high of $148.83.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. Research analysts expect that Abivax SA Sponsored ADR will post -3.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ABVX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Friday, July 17th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $187.00 target price on shares of Abivax in a report on Wednesday, July 1st. Truist Financial boosted their price objective on Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Morgan Stanley restated an “overweight” rating and set a $180.00 target price on shares of Abivax in a research note on Friday, July 24th. Finally, Leerink Partners lifted their price target on shares of Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Abivax has a consensus rating of “Moderate Buy” and an average price target of $156.50.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.